Want to see HIMS full AI Analyst Report?

Hims & Hers Health (HIMS) Stock Forecast & Price Target

9,909 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HIMS Analyst Ratings

Hold

3 Buy

10 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Hims

& Hers Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HIMS Stock 12 Month Forecast

Average Price Target

$32.90

▲(10.29% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Hims & Hers Health in the last 3 months. The average price target is $32.90 with a high forecast of $42.00 and a low forecast of $26.00. The average price target represents a 10.29% change from the last price of $29.83.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","36":"$36","57":"$57","25.5":"$25.5","46.5":"$46.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$42.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$26.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,25.5,36,46.5,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.44,29.483076923076926,30.526153846153846,31.56923076923077,32.612307692307695,33.65538461538462,34.69846153846154,35.74153846153846,36.784615384615385,37.82769230769231,38.87076923076923,39.91384615384615,40.956923076923076,{"y":42,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.44,28.783076923076923,29.126153846153848,29.46923076923077,29.812307692307694,30.155384615384616,30.498461538461537,30.841538461538462,31.184615384615384,31.527692307692305,31.87076923076923,32.213846153846156,32.55692307692308,{"y":32.9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.44,28.252307692307692,28.064615384615387,27.876923076923077,27.68923076923077,27.501538461538463,27.313846153846153,27.126153846153848,26.93846153846154,26.75076923076923,26.563076923076924,26.375384615384615,26.18769230769231,{"y":26,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":41.53,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":56.31,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":45.46,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":37.51,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":32.47,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.44,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":16.48,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.84,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.41,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.76,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.57,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.77,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.44,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$42.00

Average Price Target$32.90

Lowest Price Target$26.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Brian Tanquilut

Jefferies

$31

Hold

3.92%

Upside

Reiterated

09/03/26

Analysts Conflicted on These Healthcare Names: ClearPoint Neuro (NASDAQ: CLPT), Hims & Hers Health (NYSE: HIMS) and Phreesia (NYSE: PHR)

Justin Patterson

KeyBanc

―

Hold

―

Reiterated

09/02/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Hims & Hers Health (NYSE: HIMS) and Oxford BioMedica (Other OTC: OXBDF)

Jailendra Singh

Truist Financial

$27→$32

Hold

7.27%

Upside

Reiterated

08/25/26

Hims & Hers price target raised to $32 from $27 at TruistHims & Hers price target raised to $32 from $27 at Truist

Glen Santangelo

Barclays

$39→$35

Buy

17.33%

Upside

Reiterated

08/20/26

Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (NYSE: HIMS) and ProMIS Neurosciences (NASDAQ: PMN)

Daniel Grosslight

Citi

$35→$33

Hold

10.63%

Upside

Reiterated

08/12/26

Hims & Hers price target lowered to $33 from $35 at CitiHims & Hers price target lowered to $33 from $35 at Citi

Mark Mahaney

Evercore ISI

―

Hold

―

Reiterated

08/11/26

Analysts Conflicted on These Healthcare Names: Silence Therapeutics (NASDAQ: SLN), Hims & Hers Health (NYSE: HIMS) and Syndax Pharmaceuticals (NASDAQ: SNDX)

Maria Ripps

Canaccord Genuity

$40

Buy

34.09%

Upside

Reiterated

08/11/26

Analysts Are Bullish on Top Healthcare Stocks: Hims & Hers Health (HIMS), TELA Bio (TELA)

Allen Lutz

Bank of America Securities

$30→$32

Hold

7.27%

Upside

Reiterated

08/11/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: BridgeBio Pharma (NASDAQ: BBIO), Hims & Hers Health (NYSE: HIMS) and Definitive Healthcare Corp (NASDAQ: DH)

Craig Hettenbach

Morgan Stanley

$21→$28

Hold

-6.13%

Downside

Assigned

08/11/26

Hims & Hers price target raised to $28 from $21 at Morgan StanleyHims & Hers price target raised to $28 from $21 at Morgan Stanley

George Hill

Deutsche Bank

$25→$26

Hold

-12.84%

Downside

Assigned

08/11/26

Hims & Hers price target raised to $26 from $25 at Deutsche BankHims & Hers price target raised to $26 from $25 at Deutsche Bank

Jonna Kim

TD Cowen

$25→$30

Hold

0.57%

Upside

Assigned

08/11/26

Analysts Offer Insights on Healthcare Companies: Zentalis Pharmaceuticals (NASDAQ: ZNTL), Agilon Health (NYSE: AGL) and Hims & Hers Health (NYSE: HIMS)

David Larsen

BTIG

―

Hold

―

Assigned

08/11/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Hims & Hers Health (NYSE: HIMS), Merit Medical Systems (NASDAQ: MMSI) and Intuitive Surgical (NASDAQ: ISRG)

Ryan MacDonald

Needham

$35→$42

Buy

40.80%

Upside

Reiterated

08/11/26

Hims & Hers: Strong GLP-1-Driven Momentum, Strategic AI & International Investments Underpin Buy Rating and Raised $42 Price Target

Cory Carpenter

J.P. Morgan

$35→$33

Buy

10.63%

Upside

Reiterated

05/12/26

Hims & Hers price target lowered to $33 from $35 at JPMorganHims & Hers price target lowered to $33 from $35 at JPMorgan

Michael Cherny

Leerink Partners

―

Hold

―

Reiterated

04/16/26

Push to ease peptide restrictions positive for Hims & Hers, says Leerink Push to ease peptide restrictions positive for Hims & Hers, says Leerink

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Brian Tanquilut

Jefferies

$31

Hold

3.92%

Upside

Reiterated

09/03/26

Analysts Conflicted on These Healthcare Names: ClearPoint Neuro (NASDAQ: CLPT), Hims & Hers Health (NYSE: HIMS) and Phreesia (NYSE: PHR)

Justin Patterson

KeyBanc

―

Hold

―

Reiterated

09/02/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Hims & Hers Health (NYSE: HIMS) and Oxford BioMedica (Other OTC: OXBDF)

Jailendra Singh

Truist Financial

$27→$32

Hold

7.27%

Upside

Reiterated

08/25/26

Hims & Hers price target raised to $32 from $27 at TruistHims & Hers price target raised to $32 from $27 at Truist

Glen Santangelo

Barclays

$39→$35

Buy

17.33%

Upside

Reiterated

08/20/26

Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (NYSE: HIMS) and ProMIS Neurosciences (NASDAQ: PMN)

Daniel Grosslight

Citi

$35→$33

Hold

10.63%

Upside

Reiterated

08/12/26

Hims & Hers price target lowered to $33 from $35 at CitiHims & Hers price target lowered to $33 from $35 at Citi

Mark Mahaney

Evercore ISI

―

Hold

―

Reiterated

08/11/26

Analysts Conflicted on These Healthcare Names: Silence Therapeutics (NASDAQ: SLN), Hims & Hers Health (NYSE: HIMS) and Syndax Pharmaceuticals (NASDAQ: SNDX)

Maria Ripps

Canaccord Genuity

$40

Buy

34.09%

Upside

Reiterated

08/11/26

Analysts Are Bullish on Top Healthcare Stocks: Hims & Hers Health (HIMS), TELA Bio (TELA)

Allen Lutz

Bank of America Securities

$30→$32

Hold

7.27%

Upside

Reiterated

08/11/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: BridgeBio Pharma (NASDAQ: BBIO), Hims & Hers Health (NYSE: HIMS) and Definitive Healthcare Corp (NASDAQ: DH)

Craig Hettenbach

Morgan Stanley

$21→$28

Hold

-6.13%

Downside

Assigned

08/11/26

Hims & Hers price target raised to $28 from $21 at Morgan StanleyHims & Hers price target raised to $28 from $21 at Morgan Stanley

George Hill

Deutsche Bank

$25→$26

Hold

-12.84%

Downside

Assigned

08/11/26

Hims & Hers price target raised to $26 from $25 at Deutsche BankHims & Hers price target raised to $26 from $25 at Deutsche Bank

Jonna Kim

TD Cowen

$25→$30

Hold

0.57%

Upside

Assigned

08/11/26

Analysts Offer Insights on Healthcare Companies: Zentalis Pharmaceuticals (NASDAQ: ZNTL), Agilon Health (NYSE: AGL) and Hims & Hers Health (NYSE: HIMS)

David Larsen

BTIG

―

Hold

―

Assigned

08/11/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Hims & Hers Health (NYSE: HIMS), Merit Medical Systems (NASDAQ: MMSI) and Intuitive Surgical (NASDAQ: ISRG)

Ryan MacDonald

Needham

$35→$42

Buy

40.80%

Upside

Reiterated

08/11/26

Hims & Hers: Strong GLP-1-Driven Momentum, Strategic AI & International Investments Underpin Buy Rating and Raised $42 Price Target

Cory Carpenter

J.P. Morgan

$35→$33

Buy

10.63%

Upside

Reiterated

05/12/26

Hims & Hers price target lowered to $33 from $35 at JPMorganHims & Hers price target lowered to $33 from $35 at JPMorgan

Michael Cherny

Leerink Partners

―

Hold

―

Reiterated

04/16/26

Push to ease peptide restrictions positive for Hims & Hers, says Leerink Push to ease peptide restrictions positive for Hims & Hers, says Leerink

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

BLTEBelite Bio, Inc. ADR

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hims & Hers Health

3 Months

Maria RippsCanaccord Genuity

Success Rate

11/16 ratings generated profit

Average Return

+22.32%

Copying Maria Ripps's trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +22.32% per trade.

1 Year

Glen SantangeloBarclays

Success Rate

10/13 ratings generated profit

Average Return

+26.95%

Copying Glen Santangelo's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +26.95% per trade.

2 Years

Glen SantangeloBarclays

Success Rate

10/13 ratings generated profit

Average Return

+27.82%

Copying Glen Santangelo's trades and holding each position for 2 Years would result in 76.92% of your transactions generating a profit, with an average return of +27.82% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HIMS Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HIMS has received 7 Buy Ratings, 23 Hold Ratings, and 0 Sell Ratings. HIMS average Analyst price target in the past 3 months is 32.90.

Each month's total comprises the sum of three months' worth of ratings.

HIMS Financial Forecast

HIMS Earnings Forecast

Next quarter’s earnings estimate for HIMS is $0.06 with a range of -$0.05 to $0.20. The previous quarter’s EPS was -$0.37. HIMS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year HIMS has Performed in-line its overall industry.

HIMS Sales Forecast

Next quarter’s sales forecast for HIMS is $892.84M with a range of $883.78M to $901.60M. The previous quarter’s sales results were $753.21M. HIMS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year HIMS has Performed in-line its overall industry.

HIMS Stock Forecast FAQ

What is HIMS’s average 12-month price target, according to analysts?

Based on analyst ratings, Hims & Hers Health’s 12-month average price target is 32.90.

What is HIMS’s upside potential, based on the analysts’ average price target?

Hims & Hers Health has 10.29% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is HIMS a Buy, Sell or Hold?

Hims & Hers Health has a consensus rating of Hold which is based on 3 buy ratings, 10 hold ratings and 0 sell ratings.

What is Hims & Hers Health’s price target?

The average price target for Hims & Hers Health is 32.90. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $42.00 ,the lowest forecast is $26.00. The average price target represents 10.29% Increase from the current price of $29.83.

What do analysts say about Hims & Hers Health?

Hims & Hers Health’s analyst rating consensus is a Hold. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of HIMS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Hims & Hers Health (HIMS) Stock Forecast & Price Target

HIMS Analyst Ratings

HIMS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Hims & Hers Health

HIMS Analyst Recommendation Trends

HIMS Financial Forecast

HIMS Earnings Forecast

HIMS Sales Forecast

HIMS Stock Forecast FAQ

Detailed List of Analyst Forecasts